Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of “Moderate Buy” from Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has received a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation, one has given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $32.00.

Several research analysts have weighed in on the stock. Truist Financial raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Oppenheimer cut Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Stephens set a $32.00 target price on Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Wall Street Zen lowered Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $35.00 to $31.50 in a report on Thursday, May 28th.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX remained flat at $31.47 during mid-day trading on Friday. 1,346,611 shares of the stock were exchanged, compared to its average volume of 1,877,165. The firm’s fifty day moving average is $31.24 and its 200-day moving average is $26.76. The company has a market capitalization of $3.85 billion, a PE ratio of 18.09, a P/E/G ratio of 0.96 and a beta of 0.74. Catalyst Pharmaceuticals has a one year low of $19.05 and a one year high of $32.56.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Deerfield Management Company L.P. boosted its holdings in Catalyst Pharmaceuticals by 72.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after purchasing an additional 2,095,291 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Catalyst Pharmaceuticals by 200.6% during the fourth quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock worth $40,124,000 after purchasing an additional 1,147,565 shares during the period. Morgan Stanley raised its position in shares of Catalyst Pharmaceuticals by 59.1% in the fourth quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock valued at $68,466,000 after buying an additional 1,089,775 shares in the last quarter. Bank of America Corp DE raised its position in shares of Catalyst Pharmaceuticals by 38.0% in the first quarter. Bank of America Corp DE now owns 3,036,546 shares of the biopharmaceutical company’s stock valued at $75,185,000 after buying an additional 836,704 shares in the last quarter. Finally, Fundsmith LLP raised its position in shares of Catalyst Pharmaceuticals by 24.2% in the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock valued at $66,267,000 after buying an additional 654,721 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).